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Background/aim: We aimed to define the optimal SUVmax cut-off value in determination of mediastinal–hilar lymph node metastasis,
by comparing positive PET/CT results with the results of endobronchial ultrasound guided transbronchial needle aspiration biopsy
(EBUS-TBNA).
Materials and methods: Thirty-one patients with malignancy whose PET/CT imaging revealed a hypermetabolic mediastinal and/
or hilar lymph node and who had undergone EBUS-TBNA were evaluated retrospectively. Histopathology was regarded as the gold
standard. The diagnostic role of PET/CT in mediastinal/hilar lymph node metastasis was investigated and compared with the results of
contrast-enhanced CT.
Results: When a SUVmax value of 2.5 was used, the sensitivity, positive predictive value (PPV), and diagnostic accuracy of the PET/CT
were 100%, 65.4%, and 65.4% respectively. In the ROC analysis, the SUVmax cut-off value with the highest diagnostic accuracy (75%)
was calculated as 6.3, and when this value was considered, the sensitivity, specificity, PPV, negative predictive value, and diagnostic
accuracy of the PET/CT were determined as 70.6%, 83.3%, 88.9%, 60%, and 75% respectively (AUC: 0.779). The sensitivity, PPV, and
diagnostic accuracy of the thorax CT were calculated as 91.1%, 72%, and 71.1%, respectively.
Conclusion: When determining mediastinal–hilar lymph node metastasis via PET/CT, although a SUVmax cut-off value of 6.3 increases
specificity and diagnostic accuracy, we think that a SUVmax cut-off value of 2.5 and above give more optimal results in routine practice.
Key words: PET/CT, mediastinal–hilar lymph nodes, EBUS-TBNA

1. Introduction
Mediastinal staging plays an important role in many
pulmonary and extrapulmonary malignant neoplasms,
in evaluation of suitability of patients for operation,
scheduling treatment opportunities, and determination of
prognosis (1). For this purpose, invasive and noninvasive
methods are in use. Among the noninvasive methods
are, thorax computed tomography, magnetic resonance
imaging (MRI), and 18-fluorine-2-deoxyglucose-positron
emission tomography/computed tomography (18F-FDG
PET/CT), while transbronchial needle aspiration biopsy
(TBNA), transthoracic needle aspiration biopsy (TTNA),
endobronchial ultrasound guided transbronchial needle
aspiration biopsy (EBUS-TBNA), endoesophageal
ultrasound (EUS) guided lymph node biopsy, cervical
mediastinoscopy, mediastinotomy, and video-assisted
* Correspondence: aytugzuhal@yahoo.com
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thoracoscopy are some of the invasive methods. Thorax
CT is the first method in mediastinal staging and is used
for the evaluation of lymph node dimensions; however,
PET/CT gives information about not only the size but also
the metabolic activities of lymph nodes and is a functional
alternative to contrast-enhanced CT (2). Nevertheless,
these methods are not sensitive or determinant enough for
the investigation of mediastinal lymph node metastasis.
Thus, the diagnosis of lymph nodes that are hypermetabolic
with PET/CT and larger than 10 mm in diameter with
thorax CT should be corrected histopathologically with
minimally invasive or invasive methods (3,4). In this
study, we aimed to determine the optimal SUVmax cut-off
value in determination of mediastinal–hilar lymph node
metastasis by comparing positive PET/CT results with the
results of EBUS-TBNA.

KANDEMİR et al. / Turk J Med Sci
2. Materials and methods
2.1. Patient selection
Thirty one patients (27 male and 4 female with a mean
age of 56.1 ± 13.7 years and ages ranging from 19 to 79
years) whose PET/CT images revealed a hypermetabolic
mediastinal and/or hilar lymph node were included in
this retrospective study (Table 1). Following PET/CT,
all patients underwent an EBUS-TBNA. Moreover, a
contrast-enhanced thorax CT of all patients existed. The
results of the PET/CT and thorax CT were compared
with the histopathologic results obtained from the EBUSTBNA. Histopathological evaluation was regarded as the
gold standard and the optimal SUVmax cut-off value in
PET/CT was investigated.
2.2. Thorax CT imaging protocol
Thorax CT was used for evaluation of the size of
mediastinal–hilar lymph nodes. After the intravenous
injection of contrast material into all patients, CT images
with 2-mm-thick slices were taken from the supraclavicular
region to the adrenal glands. The radiologists were
informed about the clinic data and the results of other
imaging techniques of the patients. Mediastinal lymph
nodes with a short diameter larger than 10 mm were
suspected of being metastatic.
2.3. PET/CT imaging protocol
The PET/CT imaging was performed on a high-resolution
PET scanner (Siemens Biograph 6; Germany) that was
integrated with a 6-slice multidetector CT. All patients
were asked to fast for 6 h before the PET/CT scan and then
were injected intravenously with a 0.15 mCi/kg dose of
18F FDG after their blood glucose levels were determined
to be appropriate (<150 mg/dL). After a resting period
of 45–60 min in a quiet and relaxing room without any
activity, a whole body scan was performed using the PET/
CT. The CT scans were obtained as 5-mm-thick slices, with
energy of 130 KV and 90 mA. The PET emission images
were obtained with approximately 5–7 bed positions for
4 min per bed position from the skull base to the midthigh. Fusion images were obtained after CT-based
attenuation corrections and iterative reconstructions
were done. By investigation of the tomographic scans,
pathologic metabolic activity foci were evaluated visually
and quantitatively. Lymph nodes with a higher FDG
uptake from the blood pool on mediastinal backward and
with a SUVmax value higher than 2.5 were suspected for
metastasis.
2.4. Lymph node sampling (EBUS-TBNA procedure)
The lymph nodes observed in the thorax CT and PET/
CT scans were sampled by the assistance of a convex
probe EBUS (7.5 MHz, BF-UC160F; Olympus Optical
Co., Tokyo, Japan) with the help of real-time imaging
after conscious sedation of the patients was achieved by

intermittent intravenous midazolam and/or phentanyl
injections. The samples were obtained from the right
and left paratracheal (2R, 2L), right and left inferior
paratracheal (4R, 4L), right and left hilar (10R, 10L),
right interlobar, (11R) and subcarinal (7) locations. The
punctures were created using a 22-gauge EBUS needle.
With the aid of Doppler ultrasound, we avoided damaging
the vascular structures. We attempted to obtain at least
3 samples from each lymph node. One portion of the
material on the needle was dispersed over a dry slide at
room temperature while another portion was used to
prepare dispersions on a formaldehyde + alcohol mixture.
Another portion of it was also used for the formation of a
cellular block on liquid with formaldehyde and was sent to
the pathology laboratory. Immunohistochemical studies
were performed when necessary. In this study, appropriate
histochemical stainings such as pankeratin, TTF-1, LCA
TDT, P63, CK5/6, CD3, CD20, CD30, CD15, CK7, CK20,
CD56, CDX2, CD99, WT-1, CD117, S100, PSA, napsin A,
fascin, ALK, EMA, granzyme B, Ki 67, desmin, myogenin,
NSE, chromogranin, smooth muscle actin, cyclin-D1,
synaptophysin, vimentin, surfactant, and protein A were
used.
2.5. Statistical analysis
Statistical analyses were performed using SPSS for
Windows, version 21.0. Numeric variations are
summarized with mean ± standard deviation and (min–
max) values, while qualitative variations are summarized
with numbers and percentages. The power of the SUVmax
value in determination of malignancy diagnosed with
EBUS-TBNA is investigated with the area under the
receiver operating characteristic (ROC) curve. For this
value, the area under the curve (AUC) percentage is
estimated. The cut-off value for SUVmax along with the
sensitivity, specificity, negative predictive value, positive
predictive value, and diagnostic accuracy for this cutoff point were assessed. The comparison of diagnostic
accuracies of PET/CT and thorax CT were estimated with
a chi-square test. The significance value was regarded as P
< 0.05.
3. Results
In this study, 52 mediastinal–hilar lymph nodes that were
hypermetabolic on a PET/CT scan and underwent EBUSTBNA were evaluated. The lymph nodes came from 31
patients, 16 of whom were diagnosed with lung cancer while
15 had extrapulmonary cancers; the histopathological
diagnoses of the patients are summarized in Table 1.
3.1. Results of EBUS-TBNA
TBNA was performed on 28 mediastinal and 24 hilar
lymph nodes of 31 patients under EBUS. Eleven of the
lymph nodes were paratracheal, 24 were hilar, 16 were
subcarinal, and 1 was interlobar in location. Furthermore,
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Table 1. Patient descriptions and characteristics of the lymph nodes.
Number of patients (n)

31

Male / female

27 / 4

Average patient age; age range

56.1 ± 13.7; (19–79)

Final histopathological diagnosis of the lung cancer and
extrathoracic malignancy

Patients

MLN

BLN

(n = 31)

(n = 34)

(n = 18)

Small-cell carcinoma

2

2

0

Nonsmall cell carcinoma (squamous cell carcinoma)

4

5

1

Nonsmall cell carcinoma(adenocarcinoma)

9

15

3

Other (nonsmall carcinoma with an unidentified subcategory) 1

0

2

Hodgkin’s lymphoma

3

2

1

Non-Hodgkin’s lymphoma

1

2

0

0

1

Tonsillar carcinoma
Bladder carcinoma

2

2

1

Laryngeal carcinoma

3

0

6

Breast carcinoma

1

1

1

Nasal squamous cell carcinoma

1

0

2

Rhabdomyosarcoma

1

3

0

Gastric adenocarcinoma

1

1

0

Leiomyosarcoma

1

1

0

The location and number of the suspected lymph
nodes according to CT, PET/CT, and EBUS-TBNA

EBUS-TBNA
CT

PET/CT

EBUS

MLN

BLN

(n = 43)

(n = 52)

(n = 52)

(n = 34)

(n = 18)

Right upper paratracheal (2R)

3

3

3

3

0

Right lower paratracheal (4R)

5

7

7

4

3

Left lower paratracheal (4L)

1

1

1

1

0

Right hilar

(10R)

15

16

16

12

4

Left hilar

(10L)

5

8

8

4

4

Right interlobar

(11R)

1

1

1

0

1

(7)

13

16

16

10

6

Subcarinal

MLN = malignant lymph node, BLN = benign lymph node, EBUS-TBNA = endobronchial ultrasound guided transbronchial needle
aspiration biopsy, CT = computed tomography, PET/CT = positron emission tomography/computed tomography, and SUVmax =
maximum standardized uptake value.

34 were evaluated as malignant and 18 were benign
in histopathologic investigation. Among the benign
lesions, 10 were compatible with anthracosis, 7 were
degeneration, and one was granulomatous inflammation.
The histopathological diagnosis and the distribution of
malignant/benign lymph nodes according to localization
are summarized in Table 1.
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3.2. PET/CT imaging results
Among the 31 patients with 21 localizations in the
mediastinal–hilar region, in total 140 lymph nodes with
increased metabolic activity were determined with PET/
CT. Among these 140 lymph nodes, 52 were sampled
with EBUS-TBNA. The mean SUVmax value of these 52
lymph nodes was 8.56 ± 5.9 (min–max: 2.9–29). In 34
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(65.4%) of the total 52 locations determined with PET/
CT, a true positive was investigated (Figures 1A–1F). The
mean SUVmax value of the 34 malign lymph nodes was
calculated as 10.23 ± 6.23 (min–max: 3.1–29), while the
mean SUVmax value of the 18 benign lymph nodes was
5.42 ± 3.87 (min–max: 2.9–18.5) and the difference was
statistically significant (P < 0.05). The mean of the short
diameters of the 52 lymph nodes sampled with EBUSTBNA was 19.9 ± 10.7 mm (min–max: 6–46). The mean of
the short diameters of the malignant lymph nodes was 24.1
± 10.7 mm (min–max: 11–46), that of the benign lymph
nodes was calculated as 12.1 ± 4.0 mm (min–max: 6–20),
and the difference was statistically significant (P < 0.05).
In 18 (34.6%) of the total 52 locations determined with
PET/CT, a false positive was investigated. Among those
18 false positive localizations, 7 were degeneration, 10
were anthracosis, and 1 was granulomatous inflammation
(Figures 2A–2D). When a SUVmax value of 2.5 is
regarded, the sensitivity, PPV, and diagnostic accuracy
of PET/CT in determination of malignant lymph nodes
were 100%, 65.4%, and 65.4%, respectively. In the ROC
analysis with the histopathologic evaluation regarded as
gold standard, the SUVmax cut-off value with the highest
diagnostic accuracy was calculated as 6.3; and when this
value was considered, sensitivity, specificity, PPV, NPV,
and diagnostic accuracy of PET/CT were determined
as 70.6%, 83.3%, 88.9%, 60.0%, and 75%, respectively,
and AUC was estimated as 0.779 (Table 2). Since PET/
CT enables scanning of the whole body, it supplied an
additional contribution to staging in 13 (41.9%) of the
31 patients with the determination of distant metastasis
(Figure 2E). Moreover, in 3 patients with a diagnosis of
extrapulmonary malignancies, it identified lymph node
metastasis owing to a second primary lung malignancy
and the last histopathologic diagnosis for those patients
was reported as squamous cell carcinoma.
3.3. Results of thorax CT scans
Among the 31 patients with 10 localizations in the
mediastinal–hilar region, in total 75 lymph nodes larger
than 10 mm were determined with thorax CT scans.
Nine of the 52 lymph nodes, which were determined
with PET/CT and underwent EBUS-TBNA, could not
be determined with thorax CT. In that aspect, among the
75 lymph nodes, 43 were sampled with EBUS-TBNA.
Among those 43 lymph nodes, 31 were malignant and 12
were benign, with a mean short diameter of 21.8 ± 10.6
mm (min–max: 10–45). The mean short diameter of the
malignant lymph nodes was 25.1 ± 10.3 mm (min–max:
10–45), that of the benign lymph nodes was calculated
as 13.4 ± 5.4 mm (min–max: 10–28), and the difference
was statistically significant (P < 0.05). In 12 (23.07%) of
the total 52 locations determined with thorax CT, a false
positive was investigated. Among those 12 false positive

localizations, 6 were degeneration, 5 were anthracosis, and
1 was granulomatous inflammation. Thorax CT could not
determine a total of 9 (3 malignant and 6 benign) lymph
nodes (17.3%) in 5 patients, which were determined by
PET/CT and diagnosed with histopathological evaluation.
Thus, in this study, in total 3 lymph nodes of 2 patients,
which were determined by PET/CT and diagnosed with
histopathological evaluation but could not be determined
in CT, were regarded as false negative (5.76%). When
the short diameter is defined as 10 mm, the sensitivity,
specificity, NPV, PPV, and diagnostic accuracy of thorax
CT were calculated as 91.1%, 33.3%, 33.3%, 72%, and
71.1%, respectively, in malignant mediastinal–hilar lymph
node determination for these 52 lymph nodes.
4. Discussion
The cytological and histological diagnosis of suspected
mediastinal and/or hilar lymph nodes is critically important
in staging, planning treatment, and determining prognosis
in pulmonary and extrapulmonary malignancies. Though
histopathology is the gold standard in evaluation of lymph
node metastasis, imaging techniques also play an important
role. In this study, it was aimed to determine the diagnostic
role of PET/CT in the evaluation of mediastinal–hilar
lymph node metastasis in pulmonary and extrapulmonary
malignancies and to compare that with contrast-enhanced
CT, where histopathologic investigation with EBUS-TBNA
is regarded as the gold standard. The most commonly used
standard method in mediastinal staging is the thorax CT.
With respect to the anatomical imaging, lymph nodes
larger than 10 mm in CT are suspected of having malignant
infiltration (5). However, it has been determined that
micrometastasis may be present in 20% of lymph nodes
smaller than 10 mm while larger lymph nodes may
actually be benign (6). In this study, false positivity was
determined in 12 of 52 lymph nodes evaluated with EBUSTBNA. In a mean follow-up of 15 months with clinical and
radiological evaluations done every 3 months, no increase
in the size of lymph nodes or progression has been
determined in this group of patients. On the other hand,
thorax CT could not identify 9 (3 malignant, 6 benign)
lymph nodes in 5 patients, which were determined by
PET/CT and proved histopathologically. Thereby, in this
study, 3 lymph node metastasis in 2 patients, defined in
PET/CT and diagnosed as malignant histopathologically
but could not be determined in CT, were evaluated as false
negativity (5.76%). When the EBUS-TBNA data of these
patients were evaluated, it was determined that one was
diagnosed with adenocarcinoma and the diagnosis of the
other patient was squamous cell carcinoma. When the
sizes of lymph nodes were evaluated, it was determined
that all 3 malign lymph nodes were larger than 10 mm.
Benign lymph nodes were smaller than 10 mm and 3
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Figure 1. A representative case of true positive mediastinal PET/CT scan findings, with mediastinal metastases detected by EBUSTBNA. A: The transaxial CT scan of a 54-year-old man with adenocarcinoma in the right upper lobe. The right lower paratracheal
lymph node (4R) measures 32 × 37 mm. The right hilar lymph node (10R) was 18 mm in diameter. Both lymph nodes were considered
positive for metastasis from CT. B: The transaxial PET scan demonstrates pathologic FDG uptake in the right upper lobe tumor (T),
right lower paratracheal (4R), and right hilar (10R) lymph node. C: The transaxial PET/CT fusion scan demonstrates pathologic FDG
uptake in the right upper lobe tumor (T), right lower paratracheal (4R), and right hilar (10R) lymph nodes. D: The PET/CT MIP scan
also demonstrates pathologic FDG accumulation in the tumor (T), mediastinal lymph nodes suggesting another mediastinal lymph
node, and distant metastasis (sacral). E: EBUS-TBIA of the right lower paratracheal (4R) F: The right hilar (10R) lymph node showing a
needle within the lymph node. Based on the final histopathologic diagnosis, the result of the PET/CT scan was a malignant lymph node.

other lymph nodes were thought to be undetermined due
to their localization. This indicated that thorax-CT could
not determine 6 of the 52 lymph nodes even though they
were larger than 10 mm in size. In many studies and metaanalyses, it has been determined that thorax CT has a
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limited sensitivity (43%–81%) and accuracy (59%–85%)
ratios while its specificity is lower in mediastinal staging
(7). In our study, the sensitivity and diagnostic accuracy of
thorax CT in the determination of malignant mediastinal–
hilar lymph nodes were estimated as 91.1% and 71.1%,

KANDEMİR et al. / Turk J Med Sci

Figure 2. A representative case of false positive mediastinal PET/CT scan findings, with EBUS-TBNA histopathologic results consisted
with degenerative lymph nodes. A: The transaxial CT scan demonstrates that the calcified subcarinal lymph node (7) was 20 mm in
diameter. B: The transaxial PET scan demonstrates the pathologic FDG uptake in the subcarinal (7) lymph node. C: The transaxial
PET/CT fusion scan demonstrates the pathologic FDG uptake in the subcarinal (7) lymph node. D: EBUS-TBIA of the subcarinal (7),
showing a needle within the lymph node. Based on the final histopathologic diagnosis, the result of the PET/CT scan was a false positive
lymph node. E: The PET/CT MIP scan also demonstrates pathologic FDG accumulation in the primary tumor (nasal SCC).
Table 2. The sensitivity, specificity, diagnostic accuracy, and negative/positive predictive values of PET/CT according to SUVmax cut-off
values.
PET/CT
SUV max cut-off

Sensitivity
%

Specificity
%

NPV
%

PV
%

Diagnostic accuracy
%

2.5

100

–

–

65.4

65.4

6.3

70.6

83.3

60

88.9

75

AUC (%)
77.9

PET/CT = positron emission tomography/computed tomography, SUVmax = maximum standardized uptake value, NPV = negative
predictive value, PPV = positive predictive value, and AUC = area under curve.

respectively. The reason for the high sensitivity determined
in our study was that only lymph nodes determined as
positive in the PET/CT were included in the study. It is
difficult to identify lymph nodes smaller than 10 mm in
PET/CT.
PET/CT is a noninvasive imaging technique that is
used in mediastinal staging, follow-up, determination of
recurrences after treatment, investigation of distant
metastasis, investigation of responses to treatment, and

prognosis of both pulmonary and extrapulmonary
malignancies. It allows whole body scanning and it can
give both anatomical and functional data together (8).
Toloza et al. have found the sensitivity, specificity, PPV,
and NPV of PET/CT in the determination of malignant
mediastinal–hilar lymph nodes to be as high as 84%, 89%,
79%, and 93%, respectively (9). Recently, many studies on
the place of PET in determination of mediastinal metastasis
that compare PET with other conventional imaging
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techniques have been performed; PET/CT has been
reported to be superior to CT in many studies and metaanalyses, especially in mediastinal staging of operable
nonsmall cell lung cancer (9,10). However, since FDG is
not specific to the tumor, high false positivity ratios are
reported in PET/CT studies due to some benign conditions,
especially including active tuberculosis, sarcoidosis,
coccidioidomycosis, aspergillosis, histoplasmosis, other
fungal infections, and reactive hyperplasia secondary to
pneumonia. This ratio is reported as 16%–55% in the
literature (9,11). In another study, it has been determined
that not only the active inflammation, but also the healed
or inactive pulmonary diseases (antecedent tuberculosis,
silicosis, anthracosis) may potentially result in increased
FDG capture in hilar or mediastinal lymph nodes (12).
False positivity was determined in 34.6% of lymph nodes
detected in PET/CT imaging in our study group. The
reasons for the false positivity were anthracosis,
degeneration, and granulomatous inflammation. The
existence of lymph nodes with FDG emission owing to
anthracosis and degeneration in our study support the
data that inactive pulmonary processes may also result in
false positivity. Navani et al. performed TBNA under
EBUS to the mediastinal lymph nodes in a study of 161
patients; in the patients who were not diagnosed with
malignancy or any other specific diseases, they performed
mediastinoscopy or they followed up with clinical and
radiological findings for 15 months as in our study. The
sensitivity, negative predictive value for malignancy, and
overall accuracy for EBUS-TBNA were 87%, 73%, and
88%, respectively (13). In another study, Chhajed et al.
determined that EBUS-TBNA has a good diagnostic yield
on conventional TBNA negative mediastinal–hilar
lymphadenopathy (14). At an average of 5%–8%, false
negative results have been achieved in bronchoalveolar
carcinoma, carcinoids, in some tumors with high mucin
levels but low metabolic activity, lesions smaller than 10
mm, and hyperglycemic patients (12). Since we included
PET/CT scans of hypermetabolic lymph nodes in our
study, we could not evaluate the causes of false negativity.
In staging studies comparing standard PET with combined
PET/CT methods in lung cancer, it has been determined
that PET/CT is more accurate in T staging; however, there
is no significant advantage between these two methods in
regards to nodal staging (15). In a study by Bellek et al. in
which the presence of N2 disease determined the decision
of surgical resection, no advantages of PET/CT compared
with CT were established and the contribution of both
methods to staging was determined to be equal (16). In
our study, similar accuracy ratios between CT and PET/
CT were determined and a significant superiority of one
these methods over the other has not been established (P >
0.05). PET/CT identified 9 lymph nodes (3 malignant and
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6 benign), which were proved histopathologically but
could not be detected by thorax CT with its hybrid imaging
advantage and multislice CT component. Moreover, PET/
CT identified distant metastasis in 41.9% of the patients
since it allows scanning of the whole body and contributed
in staging. In three patients with known extra pulmonary
malignancies, it determined lymph node metastasis due to
the second primary malignancy in lung. Since PET/CT
may give false positive results, surgical treatment should
not be avoided in any patients with lymph nodes
determined in PET/CT. The PPV of PET/CT in this study
was 88.9%. Therefore, positive lymph nodes in PET/CT
should be confirmed histopathologically with minimal
invasive methods. The gold standard method for the
diagnosis of mediastinal lymph nodes is the
mediastinoscopy. However, it is an invasive procedure and
usually requires general anesthesia and hospitalization.
Because of this, less invasive potentially alternative
methods such as TBNA, TTNA, EBUS-TBNA, and EUSNA have been developed (17). EBUS-TBNA is one of the
invasive mediastinal staging methods that are used after
PET/CT scanning according to the current guidelines
(18). In a meta-analysis including 11 studies on the role of
EBUS-TBNA in mediastinal staging with 1299 cases, the
sensitivity, specificity, and diagnostic value of EBUSTBNA were determined to be 93%, 100%, and 89%,
respectively (19). In one study, EBUS-TBNA was
performed on the mediastinal–hilar lymph nodes of
patients with known extrapulmonary malignancies for
diagnostic purposes and the sensitivity, specificity, PPV,
NPV, and diagnostic accuracy of EBUS-TBNA were
determined to be 97.4%, 100%, 100%, 87.5%, and 97.7%,
respectively (20). In the literature, there are many studies
reporting that the success rate of TBNA increases when
performed under PET/CT guidance. In a study of Hsu et
al. on 19 patients and 25 lymph nodes determined with
PET/CT, the sensitivity, specificity, and diagnostic accuracy
of TBNA biopsy was determined to be 81.8%, 100%, and
84%, respectively (21). Cömert et al. compared the results
of EBUS-TBNA and PET/CT in the determination of
malignant mediastinal lymph nodes and estimated the
sensitivity, specificity, diagnostic accuracy, NPV, and PPV
as 94.3%, 100%, 95.8%, 85.9%, 100%, respective for EBUSTBNA and 89.4%, 18.3%, 71.2%, 37.5%, and 76.0%,
respectively, for PET/CT (22). On the other hand, Yasufuku
et al., comparing the sensitivity, specificity, and diagnostic
accuracy of CT, PET, and EBUS-TBNA, determined the
results as 76.9%, 55.3%, and 60.8% for CT, 80.0%, 70.1%,
and 72.5% for PET, and 92.3%, 100%, and 98.0% for EBUSTBNA (23). In malignant–benign differentiation of PET/
CT, together with visual evaluation, a SUVmax value that
shows the FDG activity and provides a semiquantitative
analysis is also used. In many studies, the lesions with a
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SUVmax value lower than 2.5 have been determined to be
benign with a 96% sensitivity and in malignant–benign
differentiation, high sensitivity and specificity ratios were
reported when the SUVmax value is equal to or higher
than 2.5. In a study of histopathological correlation of
mediastinal lymph nodes determined with PET/CT, when
the SUVmax cut-off value was regarded as 2.5, the
sensitivity and specificity of PET/CT were estimated as
93% and 40%, respectively; when SUVmax cut-off value
was defined as 6.2 in regression analysis, the sensitivity,
specificity, and diagnostic accuracy of PET/CT were
assessed as 87%, 70%, and 77% respectively (24). In our
study, 52 lymph nodes with a SUVmax value >2.5 in PET/
CT were evaluated and among them, 18 were
histopathologically determined to be benign. At that value,
the sensitivity, PPV, and diagnostic accuracy of PET/CT
for malignant lymph node detection were determined to
be 100%, 65.4%, and 65.4% respectively. In the ROC

analysis, the SUVmax cut-off value with the highest
diagnostic accuracy (75.0%) was assessed as 6.3 (AUC:
0.779). However, if the SUVmax cut-off value was
determined to be 6.3, 10 (29.4%) of the lymph nodes that
had SUVmax values higher than 2.5 and also proved to be
malignant histopathologically could not be detected.
Because of this, though 6.3 is a cut-off value that increases
specificity and diagnostic accuracy, we think that a
SUVmax cut-off value of 2.5 results in more optimal
consequences in routine practice.
In order to determine mediastinal–hilar lymph node
metastasis in PET/CT, even though a 6.3 SUVmax cutoff value increases specificity and diagnostic accuracy,
we think that SUVmax cut-off values of 2.5 and higher
give more optimal results in routine practice. In addition,
as PET/CT has the advantage of scanning the whole
body at once and detecting distant metastasis, it plays a
supplemental role in staging.
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